Announcements Trials
Browse Landscape

Phase

Phase 2 31Phase 1 19Phase 3 18Phase 1/2 16Phase 4 6Phase NA 1

Status

Recruiting 2Completed 2Withdrawn 1Terminated 1

Sponsor Class

OTHER 3INDUSTRY 3

Study Type

Interventional 6

Sponsor

Cancer Type

Breast 6

Conditions

Breast Neoplasms 6Neoplasm Metastasis 1

Interventions

Letrozole 20Docetaxel 16Cyclophosphamide 13Zoledronic Acid 12exemestane 11Trastuzumab 11Anastrozole 11Paclitaxel 10Tamoxifen 9Capecitabine 9Fulvestrant 8Epirubicin 8pegfilgrastim 7pertuzumab 6liposomal doxorubicin 6abemaciclib 6Saline Solution 6palbociclib 5Sodium Chloride 5Dexmedetomidine 5Carboplatin 5Bupivacaine 5Bevacizumab 5ribociclib 4pegylated granulocyte colony-stimulating factor 4eribulin 4Tranexamic Acid 4Standard of Care 4Pamidronate 4Filgrastim 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 4 × Breast Neoplasms × abemaciclib × Clear all
NCT07487129 2026-03-23

Clinical and P

Beni-Suef University

Phase 4 Completed
206 enrolled
Breast

Breast Neoplasms

NCT06169371 2026-01-14

BRE-09

University of Illinois at Chicago

Phase 4 Recruiting
50 enrolled
Breast

Breast Neoplasms

NCT05362760 2025-05-16

MINERVA

University of Ulm

Phase 4 Recruiting
300 enrolled
Breast

Breast Neoplasms

NCT04707196 2023-11-24

A Study of Abemaciclib in Indian Women With Advanced Breast Cancer

Eli Lilly and Company

Phase 4 Completed
200 enrolled 10 charts
Breast

Breast Neoplasms, Neoplasm Metastasis

NCT04031885 2021-08-24

A Study of Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer

Eli Lilly and Company

Phase 4 Terminated
4 enrolled 9 charts
Breast

Breast Neoplasms

NCT03988114 2019-09-06

proMONARCH

Eli Lilly and Company

Phase 4 Withdrawn
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡